new
largescal
synthet
approach
antiretrovir
agent
r
phosphonomethoxi
propyl
r
pmpdap
develop
reaction
r
propanediol
carbon
afford
exclus
r
subsequ
use
introduct
phosphonomethyl
residu
use
tsoch
p
oipr
brch
p
oipr
follow
deprotect
ester
group
minor
ingredi
byproduct
form
process
identifi
studi
final
product
obtain
high
yield
high
enantiomer
puriti
confirm
chiral
capillari
electrophoret
analysi
use
bcyclodextrin
chiral
selector
antiretrovir
activ
data
r
pmpdap
divers
prodrug
hiv
fiv
investig
akin
r
pmpdap
prodrug
inhibit
fiv
replic
select
manner
compar
parent
molecul
amid
prodrug
less
activ
fiv
cell
cultur
wherea
alkoxyalkyl
ester
prodrug
potent
inhibit
fiv
replic
vitro
treatment
hiv
infect
nucleotid
revers
transcriptas
inhibitor
nrti
use
combin
antiretrovir
agent
highli
activ
antiretrovir
therapi
haart
base
treatment
use
combin
sever
antiretrovir
drug
prefer
past
decad
led
signific
declin
hivassoci
morbid
mortal
compound
tenofovir
disoproxil
fumar
also
approv
treatment
hepat
b
drug
oper
inhibitori
effect
toward
hbv
polymeras
present
tenofovir
becom
commerci
success
drug
treatment
hiv
hbv
infect
surprisingli
congen
tenofovir
r
phosphonomethoxi
propyl
r
pmpdap
prepar
almost
year
ago
thu
far
suffici
studi
despit
fact
potent
compar
pmpa
vitro
vivo
hand
initi
develop
hiv
drug
resist
necess
continu
search
new
antiretrovir
especi
antihiv
compound
resist
develop
despit
number
avail
drug
market
effect
global
strategi
hiv
drug
resist
prevent
work
work
describ
optim
effect
methodolog
larg
scaleprepar
r
pmpdap
promis
futur
drug
candid
treatment
hiv
andor
retrovir
infect
eventu
clinic
develop
compound
support
also
recent
progress
develop
prodrug
prepar
prodrug
improv
bioavail
parent
compound
well
pharmacolog
properti
gener
moreov
r
pmpdap
similar
mani
acycl
nucleosid
phosphon
anp
effect
human
retro
viral
infect
also
compound
great
signific
veterinari
medicin
prove
potent
inhibitor
fiv
felin
immunodefici
viru
infect
cat
purpos
current
clinic
develop
till
late
two
synthet
approach
r
phosphonomethoxi
propyl
describ
first
method
stepwis
approach
start
isobutyl
ester
lactic
acid
convert
tetrahydropyranyl
deriv
reduc
r
propanol
tosyl
synthesi
r
pmpdap
base
alkyl
thu
obtain
r
propyl
tosyl
follow
remov
etherif
free
hydroxi
group
diisopropyl
tosyloxymethanephosphon
process
also
patent
howev
total
yield
key
intermedi
r
introduct
phosphonomethyl
residu
follow
deprotect
ester
group
via
transsilyl
reaction
bromotrimethylsilan
hydrolysi
proce
total
yield
second
method
base
condens
appropri
chiral
synthon
r
bi
phosphonomethoxi
propyl
ptoluenesulfon
r
pmpsynthon
compound
prepar
r
multistep
process
involv
chloromethyl
arbuzov
reaction
triisopropyl
phosphit
catalyt
hydrogen
final
tosyl
method
appropri
laboratori
scale
synthes
work
describ
new
approach
r
pmpdap
util
nucleophil
reaction
r
propanediol
carbon
advantag
start
materi
commerci
access
high
optic
puriti
togeth
better
reactiv
higher
yield
compar
mention
r
propyl
tosyl
despit
fact
r
propanediol
carbon
involv
industri
synthesi
tenofovir
mani
synthet
detail
use
nucleobas
describ
short
commun
publish
regard
use
synthesi
r
pmpa
work
contain
experiment
detail
recent
anoth
detail
paper
industri
synthesi
tenofovir
issu
descript
byproduct
synthesi
focus
mostli
final
synthet
step
prepar
prodrug
form
tenofovir
disoproxil
analyt
method
quantif
case
base
catalyz
reaction
r
propanediol
carbon
proceed
form
desir
r
high
yield
regiospecif
posit
scheme
side
effect
formyl
one
amino
group
occur
alway
n
posit
formyl
byproduct
easili
transform
aqueou
alkali
byproduct
bi
hydroxyalkyl
deriv
elimin
product
form
longer
reaction
time
total
quantiti
mixtur
low
easili
remov
introduct
phosphonomethyl
residu
perform
use
diisopropyl
tosyloxymethanephosphon
diisopropyl
bromomethanephosphon
first
possibl
requir
protect
amino
group
reaction
perform
basic
condit
dimethylformamid
afford
desir
phosphon
ester
accompani
small
amount
n
n
formyl
deriv
bi
phosphonomethyl
deriv
also
small
amount
compound
previou
step
scheme
formyl
product
could
transform
basic
hydrolysi
desir
intermedi
subsequ
deprotect
final
product
r
pmpdap
transsilyl
reaction
bromotrimethylsilan
follow
hydrolysi
yield
final
deprotect
step
lead
r
pmpdap
rang
agreement
previous
publish
data
altern
method
prepar
phosphonomethyl
deriv
base
util
diisopropyl
bromomethanephosphon
approach
usual
requir
protect
amino
group
case
select
protect
step
dimethylformamid
dimethyl
acet
reaction
lead
preferenti
monosubstitut
product
scheme
reaction
diisopropyl
bromomethanephosphon
realiz
without
necess
isol
intermedi
fact
belong
main
advantag
process
particular
disadvantag
includ
complic
monitor
reaction
cours
due
presenc
decomposit
product
origin
dimethylaminomethylen
compound
also
lower
yield
similarli
anp
r
pmpdap
highli
polar
charact
due
presenc
free
phosphon
acid
function
henc
unfavor
pharmacolog
properti
expect
phosphon
group
subject
physiolog
ph
deproton
ioniz
drug
molecul
mostli
imperm
cellular
membran
unless
pinocytosi
involv
addit
phosphon
base
drug
thu
absorb
gastrointestin
tract
limit
scope
disqualifi
drug
oral
applic
order
achiev
oral
bioavail
intracellular
deliveri
anp
transform
appropri
prodrug
form
highli
advis
case
decid
transform
r
pmpdap
two
structur
differ
type
prodrug
alkoxyalkyl
hexadecyloxypropyl
monoest
amid
prodrug
first
type
synthes
reaction
tetrabutylammonium
salt
r
pmpdap
hexadecyloxypropyl
bromid
dmf
reaction
afford
neutral
diester
subsequ
transform
alkalin
condit
hexadecyloxypropyl
monoest
scheme
procedur
develop
origin
laboratori
appropri
phosphon
ester
ethyl
diisopropyl
treat
bromotrimethylsilan
follow
reaction
amino
acid
ester
hydrochlorid
presenc
triphenyl
phosphin
bi
disulfid
aldrithiol
basic
condit
scheme
methodolog
prepar
r
pmpdap
util
r
propanediol
carbon
enabl
achiev
final
product
extraordinari
optic
puriti
despit
divers
manner
introduct
phosphonomethyl
group
work
reaction
mixtur
enantiomer
puriti
r
pmpdap
alway
higher
chiral
analysi
product
perform
capillari
electrophoresi
ce
bcyclodextrin
bcd
chiral
selector
fast
ca
min
separ
r
enantiom
pmpdap
achiev
ce
use
mm
sodium
tetrabor
adjust
naoh
ph
background
electrolyt
run
buffer
mgml
bcd
chiral
selector
see
figur
averag
enantiomer
puriti
degre
analyz
sampl
three
batch
ac
given
tabl
high
enantiomer
puriti
synthes
r
pmpdap
batch
b
shown
figur
comparison
antihiv
antifiv
activ
r
pmpdap
prodrug
given
tabl
akin
r
pmpdap
prodrug
inhibit
fiv
replic
select
manner
compar
parent
molecul
amid
prodrug
less
activ
fiv
cell
cultur
wherea
alkoxyalkyl
ester
prodrug
potent
inhibit
fiv
replic
vitro
besid
hdp
monoest
also
reveal
surpris
activ
select
rna
virus
coxsacki
ec
lg
ml
punta
toro
viru
ec
lgml
vero
cell
investig
field
still
need
activ
found
dna
virus
felin
herpesviru
vv
hcmv
except
varicella
zoster
viru
compound
reveal
strong
activ
tk
vzv
oka
ec
lgml
tk
vzv
ec
lgml
nontox
concentr
new
structur
isol
byproductsdisubstitut
diaminopurin
deriv
bi
phosphon
deriv
subject
detail
antivir
screen
cell
cultur
unfortun
compound
show
antivir
activ
ec
lgml
toward
follow
virus
cem
scheme
exampl
prepar
amid
prodrug
r
pmpdap
synthesi
acycl
nucleosid
phosphon
r
phosphonomethoxi
propyl
type
pmp
deriv
base
util
r
propanediol
carbon
describ
detail
includ
isol
character
antivir
cytotox
screen
byproduct
form
singl
reaction
step
proven
case
antiretrovir
activ
r
pmpdap
synthesi
base
util
r
propanediol
carbon
easier
give
higher
yield
compar
origin
describ
procedur
final
product
isol
extraordinari
high
optic
puriti
describ
methodolog
applic
especi
largescal
synthes
r
pmpdap
excel
antiretrovir
activ
data
select
indic
r
pmpdap
prodrug
vitro
give
impetu
futur
vivo
experi
investig
compound
drug
candid
human
medicin
antiretrovir
infect
fiv
veterinari
medicin
thu
warrant
unless
state
otherwis
solvent
evapor
kpa
compound
dri
pa
melt
point
determin
kofler
block
uncorrect
analyt
tlc
perform
silica
gel
f
plate
merck
kgaa
darmstadt
germani
chromatograph
system
describ
text
column
chromatographi
perform
silica
gel
lm
fluka
prepar
revers
phase
hplc
separ
perform
water
delta
instrument
water
dual
k
absorb
detector
use
column
luna
phenomenex
lm
mm
xterra
prep
lm
mm
flow
mlmin
h
c
nmr
spectra
measur
bruker
avanc
spectromet
h
mhz
c
mhz
dmsod
solut
referenc
sodium
trimethylsilyl
acid
dss
residu
solvent
signal
number
system
assign
nmr
signal
outlin
figur
mass
spectra
measur
lcq
classic
instrument
use
electrospray
ioniz
esi
optic
rotat
measur
autopol
iv
polarimet
rudolph
research
analyt
usa
valu
given
deg
cm
g
chemic
ionexchang
resin
dowex
dowex
purchas
sigmaaldrich
czech
republ
r
diol
carbon
product
chemo
diisopropyl
bromomethanephosphon
diisopropyl
tosyloxymethanephosphon
synthes
institut
amid
prodrug
prepar
accord
procedur
develop
previous
laboratori
reaction
detail
character
amid
product
agreement
literatur
r
sodium
hydroxid
pearl
g
ad
stir
mixtur
g
mmol
r
carbon
g
mmol
dmf
ml
preheat
whole
mixtur
heat
till
convers
complet
h
addit
portion
r
carbon
g
sodium
hydroxid
g
ad
reaction
approx
h
reaction
cours
monitor
tlc
system
ethyl
acetateacetoneethanolwat
r
f
diaminopurin
r
f
r
f
byproduct
hot
mixtur
filter
thick
glass
frit
filtrat
evapor
residu
coevapor
toluen
ml
syrupi
residu
crystal
ethanol
afford
crude
yellowish
product
addit
recrystal
ethanol
give
g
white
crystal
addit
portion
g
obtain
crystal
mother
liquor
total
yield
tabl
antifiv
activ
cytotox
data
r
pmpdap
prodrug
sodium
hydrid
dispers
g
mmol
ad
stir
mixtur
diisopropyl
tosyloxymethanephosphon
g
mmol
intermedi
g
mmol
dmf
ml
cool
reaction
temperatur
gradual
let
warm
room
temperatur
mixtur
stir
h
acet
acid
ad
neutral
ph
mixtur
evapor
residu
chromatograph
column
silica
gel
ml
system
chloroform
methanol
elut
complex
mixtur
byproduct
g
includ
occur
first
follow
desir
product
yield
g
yellowish
foam
mixtur
byproduct
previou
process
evapor
chromatograph
silica
gel
column
system
ethyl
acetateacetoneethanolwat
follow
fraction
obtain
introduct
phosphonomethyl
residu
ii
prepar
r
phosphonomethoxi
propyl
use
protect
dimethylaminomethylen
group
n
ndimethylformamid
dimethylacet
ml
ad
suspens
g
mmol
dmf
ml
mixtur
stir
room
temperatur
h
evapor
residu
coevapor
xylen
ml
dri
vacuo
obtain
yellow
powder
n
suspens
thu
obtain
sodium
hydrid
g
mmol
dmf
ml
stir
vigor
min
diisopropyl
bromomethanephosphon
g
mmol
ad
reaction
mixtur
stir
h
room
temperatur
mixtur
neutral
acet
acid
ph
evapor
residu
mix
solut
methanol
ml
aqueou
ammonia
ml
set
asid
day
room
temperatur
evapor
residu
coevapor
absolut
ethanol
ml
dri
acetonitril
ml
acetonitril
ml
ad
follow
bromotrimethylsilan
ml
mmol
mixtur
stir
dark
room
temperatur
day
mixtur
evapor
residu
coevapor
acetonitril
follow
methanol
residu
dissolv
aqueou
ethanol
appli
onto
column
dowex
h
form
ml
elut
perform
water
l
follow
aqueou
ammonia
uv
absorb
fraction
collect
evapor
residu
dissolv
water
appli
onto
column
dowex
acet
form
ml
elut
water
separ
unreact
start
materi
contain
small
amount
purif
perform
crystal
subsequ
chromatographi
mother
liquor
system
chloroformmethanol
procedur
afford
g
recov
compound
subsequ
elut
dowex
linear
gradient
acet
acid
l
elut
pure
r
pmpdap
remain
product
releas
ion
exchang
boil
water
l
fraction
contain
evapor
residu
coevapor
water
ml
crystal
water
accord
xray
fluoresc
method
fig
prepar
sampl
contain
weight
percent
si
silyl
impur
origin
bromotrimethylsilan
remov
repeat
solid
phase
extract
solid
sampl
r
pmpdap
boil
dichloromethan
ml
yield
g
white
crystal
hrm
c
h
n
p
calcd
found
nmr
data
agreement
literatur
hexadecyloxypropyl
ester
r
phosphonomethoxi
propyl
sodium
salt
tetrabutylammonium
hydroxid
methanol
ml
ad
suspens
g
mmol
methanol
ml
thu
form
clear
solut
evapor
residu
coevapor
toluen
ml
dissolv
dmf
ml
stir
hexadecyloxypropyl
bromid
g
mmol
h
addit
ethanol
ml
mixtur
evapor
volum
heat
lithium
azid
mg
mmol
ad
two
portion
h
reaction
complet
evapor
heat
residu
naoh
ml
h
cool
room
temperatur
mixtur
neutral
acet
acid
ph
dilut
water
product
crystal
refriger
product
collect
suction
wash
water
ml
recrystal
boil
methanol
addit
recrystal
ethanol
afford
pure
product
white
crystal
yield
mg
addit
portion
obtain
mother
liquour
chromatographi
silica
gel
perform
system
ethyl
acetateacetoneethanolwat
first
combin
elut
rest
diester
follow
system
ratio
give
addit
mg
overal
yield
g
compound
antifiv
antivir
test
dissolv
sodium
bicarbon
concentr
mm
crandel
rees
felin
kidney
crfk
cell
grown
dulbecco
minimum
essenti
medium
dmem
life
technolog
contain
sodium
bicarbon
life
technolog
fetal
calf
serum
fc
biochrom
plate
total
crfk
cell
preseed
incub
h
humid
atmospher
contain
co
subsequ
cell
wash
phosphat
buffer
salin
pb
contain
lgml
deaedextran
inocul
ccid
fiv
presenc
serial
dilut
seri
test
compound
follow
h
incub
supernat
remov
cell
wash
pb
infect
cell
subsequ
overlaid
fc
contain
dmem
serial
dilut
seri
compound
ad
infect
cell
without
compound
includ
posit
control
viru
control
uninfect
cell
includ
neg
control
cell
control
plate
incub
six
day
time
viral
supernat
collect
analyz
enzymelink
immunosorb
assay
elisa
detect
fiv
antigen
total
supernat
incub
min
appli
maxisorp
plate
nunc
precoat
overnight
monoclon
antibodi
block
fc
pb
subsequ
amount
fiv
detect
monoclon
biotinyl
antibodi
follow
colorimetr
reaction
base
extravidin
peroxidas
sigma
opd
substrat
sigma
absorb
read
wavelength
nm
od
ec
valu
determin
compound
concentr
inhibit
fiv
antigen
detect
compar
viru
control
cytotox
compound
determin
incub
crfk
cell
presenc
serial
dilut
seri
compound
humidifi
condit
day
incub
viabil
cell
measur
use
celltit
aqueou
one
solut
assay
promega
per
manufactur
protocol
cc
valu
determin
compound
concentr
cell
death
compar
cell
control
cell
transform
human
lymphoblastoid
cell
line
htlv
transform
enabl
highli
sensit
infect
cell
line
chosen
avail
cell
line
effort
develop
sensit
assay
measur
potenc
cytotox
antihiv
compound
ascertain
compound
antivir
efficaci
freshli
harvest
cell
collect
preinfect
iiib
viru
advanc
biotechnolog
low
multipl
infect
moi
predetermin
concentr
viru
yield
ec
azt
lm
infect
cell
place
rotat
within
humidifi
incub
one
hour
initi
expedit
infect
process
cell
dilut
assay
medium
promptli
ad
assay
plate
densiti
cell
per
well
methodolog
workflow
compound
dilut
addit
well
assay
plate
use
cc
assay
cytopath
effect
hiv
infect
show
compound
dose
depend
luminesc
readout
via
cell
titer
glo
assay
measur
atpcel
viabil
non
compound
treat
unprotect
cell
die
exhibit
low
luminesc
readout
cell
presenc
drug
lm
azt
posit
control
expect
viabl
rel
healthi
incub
percent
luminesc
signal
calcul
given
well
given
compound
dose
base
neg
posit
treat
control
compound
potenc
data
ec
calcul
nonlinear
regress
use
pipelin
pilot
softwar
accelri
san
diego
ca
determin
compound
cytotox
compound
test
standard
highthroughput
assay
format
compound
serial
dilut
dmso
polypropylen
plate
use
biomek
fx
workstat
compound
ad
assay
plate
contain
assay
medium
rpmi
irvin
scientif
supplement
fetal
bovin
serum
fbr
hyclon
logan
ut
unitsml
penicillin
lgml
streptomycin
compound
arrang
horizont
pattern
concentr
per
compound
compound
ad
per
plate
due
low
dmso
toler
final
dmso
concentr
never
exceed
vv
assay
plate
contain
lm
puromycin
dmso
assay
medium
posit
neg
control
respect
cell
ad
volum
per
well
cell
per
well
use
biotek
uflow
workstat
biotek
winooski
vt
plate
subsequ
incub
day
incub
set
co
humid
day
cell
titer
glo
promega
ad
assay
plate
biotek
uflow
workstat
plate
subsequ
place
perkin
elmer
envis
plate
reader
minut
luminesc
signal
read
cc
valu
calcul
compound
concentr
caus
decreas
luminesc
signal
measur
toxic
calcul
nonlinear
regress
use
pipelin
pilot
softwar
accelri
san
diego
ca
analys
perform
commerci
pace
mdq
capillari
electrophoresi
ce
apparatu
beckman
coulter
fullerton
ca
usa
equip
intern
untreat
fuse
silica
capillari
outer
polyimid
coat
total
length
mm
effect
length
sampl
inject
hydrodynam
pressur
mbar
analyt
dissolv
deioniz
water
ca
mm
concentr
analys
perform
chiral
background
electrolyt
follow
composit
mm
sodium
tetrabor
adjust
naoh
ph
chiral
selector
bcyclodextrin
mgml
enantiomer
puriti
determin
ratio
peak
area
r
isom
averag
valu
three
experi
differ
